333 studies found for: Open Studies | "Macular Degeneration"
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|7||Not yet recruiting||
A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Proton Radiation Therapy for Macular Degeneration
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Age-Related Macular Degeneration
Copaxone in Age Related Macular Degeneration
Study of Dark Adaptation in Age-Related Macular Degeneration
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
† Indicates status has not been verified in more than two years